All reviews of published articles are made public. This includes manuscript files, peer review comments, author rebuttals and revised materials. Note: This was optional for articles submitted before 13 February 2023.
Peer reviewers are encouraged (but not required) to provide their names to the authors when submitting their peer review. If they agree to provide their name, then their personal profile page will reflect a public acknowledgment that they performed a review (even if the article is rejected). If the article is accepted, then reviewers who provided their name will be associated with the article itself.
Please do a final proofreading of the manuscript while in production.
# PeerJ Staff Note - this decision was reviewed and approved by Keith Crandall, a PeerJ Section Editor covering this Section #
As the validation set of samples is drawn from the same 424 individuals used to build the prognostic signature, this is a major concern. A second set of totally independent samples needs to be used for the validation studies.
The term "wholly" also needs to be changed in the abstract.
1. As colon and rectal cancer may have different prognostic factors, cancers in these two sites should be distinguished and analyzed (or at least described) separately.
2. The numbers for discovery and validation (see Table 1) need to be clear. How many of the 424 individuals were used for discovery and how many for validation? Please confirm that the numbers for these are accurate throughout the manuscript.
3. Change "wholly" in describing your lncRNA data to "total".
4. Include additional studies limitations in your discussion as relatively short follow-up time and few events. Also include text that the prognostic signature will need to be further tested in prospective studies.
This study is objected to developed and validated a nine-lncRNA prognostic signature for individual mortality risk assessment in colorectal cancer patients. The article has a good design framework. However, many similar articles have carried out the same research, so it seems that the innovation is insufficient.
1. Most of all is that the subject of article is about colorectal cancer, but the authors only used data on colon cancer of TCGA except rectal cancer. Can colon cancer represent all colorectal cancer?
2. According to Figure 1, 424 patients were included in final statistics, how did the authors divided these samples in model cohort (n=424) and validated cohort (n=424) in Table 1 ? The count here seems a bit contradictory.
3. There is limited overall survival (median 28.6 month follow up) and few events (108). For these analyses, it is very important to determine if these associations hold up in an additional cohort particularly one with longer follow up.
Molecular mechanism of these nine-lncRNA prognostic signature could be discussed.
Very clear and professional english through out the paper, I think. I am just unsure of whether "Wholly gene expression" is the correct wording, or "Whole" "Total" "Complete" would be more correct.
The research question is clear, and the attempt of developing and validating a prognostic model for colorectal cancer survival through a lnc-RNA signature is conducted to a high technical standard, and both methods and raw data is shared and described clearly.
Very nice manuscript, within aims and scope for the peer journal. The mehod for developing this prognostic tool os interesting, and well described. I think this manuscript could be of interest for readers of peer journal.
All text and materials provided via this peer-review history page are made available under a Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.